Background: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cases are High-grade serous ovarian carcinomas (HGSOCs), which are typically diagnosed at an advanced stage with multiple metastatic lesions. Taking biopsies of all sites of disease is infeasible, which challenges the implementation of stratification tools based on molecular profiling. Main body: In this review, we describe how these challenges might be overcome by integrating quantitative features extracted from medical imaging with the analysis of paired genomic profiles, a combined approach called radiogenomics, to generate virtual biopsies. Radiomic studies have been used to model different imaging phenotypes, and some radiomic signatures ha...
Abstract The application of radiogenomics in oncology has great prospects in precision medicine. Rad...
With targeted treatments playing an increasing role in oncology, the need arises for fast non-invasi...
The majority of patients with ovarian cancer ultimately develop recurrent chemotherapy-resistant dis...
Background: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
BACKGROUND: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
: Ovarian cancer, one of the deadliest gynecologic malignancies, is characterized by high intra- and...
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high g...
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high g...
BACKGROUND: Radiogenomics is the extension of radiomics through the combination of genetic and radio...
High-grade serous ovarian cancer is the most lethal gynaecological malignancy. Detailed molecular st...
Ovarian cancer (OC) is the second most common gynecological malignancy, accounting for about 14,000 ...
PURPOSE: To develop a precision tissue sampling technique that uses computed tomography (CT)-based r...
Abstract High-grade serous ovarian cancer is the most lethal gynaecological malignancy. Detailed mol...
International audienceTumor heterogeneity in ovarian cancer has been reported at the histological an...
Purpose: To develop a precision tissue sampling technique that uses computed tomography (CT)–based r...
Abstract The application of radiogenomics in oncology has great prospects in precision medicine. Rad...
With targeted treatments playing an increasing role in oncology, the need arises for fast non-invasi...
The majority of patients with ovarian cancer ultimately develop recurrent chemotherapy-resistant dis...
Background: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
BACKGROUND: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
: Ovarian cancer, one of the deadliest gynecologic malignancies, is characterized by high intra- and...
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high g...
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high g...
BACKGROUND: Radiogenomics is the extension of radiomics through the combination of genetic and radio...
High-grade serous ovarian cancer is the most lethal gynaecological malignancy. Detailed molecular st...
Ovarian cancer (OC) is the second most common gynecological malignancy, accounting for about 14,000 ...
PURPOSE: To develop a precision tissue sampling technique that uses computed tomography (CT)-based r...
Abstract High-grade serous ovarian cancer is the most lethal gynaecological malignancy. Detailed mol...
International audienceTumor heterogeneity in ovarian cancer has been reported at the histological an...
Purpose: To develop a precision tissue sampling technique that uses computed tomography (CT)–based r...
Abstract The application of radiogenomics in oncology has great prospects in precision medicine. Rad...
With targeted treatments playing an increasing role in oncology, the need arises for fast non-invasi...
The majority of patients with ovarian cancer ultimately develop recurrent chemotherapy-resistant dis...